These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, nonopioid metabolites. Hauser KF; Knapp PE; Turbek CS Exp Neurol; 2001 Mar; 168(1):78-87. PubMed ID: 11170722 [TBL] [Abstract][Full Text] [Related]
3. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779 [TBL] [Abstract][Full Text] [Related]
4. Dynorphin A(1-8): stability and implications for in vitro opioid activity. Bell KM; Traynor JR Can J Physiol Pharmacol; 1998 Mar; 76(3):325-33. PubMed ID: 9673796 [TBL] [Abstract][Full Text] [Related]
5. Nociceptive behavior induced by the endogenous opioid peptides dynorphins in uninjured mice: evidence with intrathecal N-ethylmaleimide inhibiting dynorphin degradation. Tan-No K; Takahashi H; Nakagawasai O; Niijima F; Sakurada S; Bakalkin G; Terenius L; Tadano T Int Rev Neurobiol; 2009; 85():191-205. PubMed ID: 19607971 [TBL] [Abstract][Full Text] [Related]
6. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Hauser KF; Foldes JK; Turbek CS Exp Neurol; 1999 Dec; 160(2):361-75. PubMed ID: 10619553 [TBL] [Abstract][Full Text] [Related]
7. Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. Liu B; Qin L; Yang SN; Wilson BC; Liu Y; Hong JS J Pharmacol Exp Ther; 2001 Sep; 298(3):1133-41. PubMed ID: 11504811 [TBL] [Abstract][Full Text] [Related]
8. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. Xu M; Petraschka M; McLaughlin JP; Westenbroek RE; Caron MG; Lefkowitz RJ; Czyzyk TA; Pintar JE; Terman GW; Chavkin C J Neurosci; 2004 May; 24(19):4576-84. PubMed ID: 15140929 [TBL] [Abstract][Full Text] [Related]
9. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. Merg F; Filliol D; Usynin I; Bazov I; Bark N; Hurd YL; Yakovleva T; Kieffer BL; Bakalkin G J Neurochem; 2006 Apr; 97(1):292-301. PubMed ID: 16515546 [TBL] [Abstract][Full Text] [Related]
10. Pronociceptive role of dynorphins in uninjured animals: N-ethylmaleimide-induced nociceptive behavior mediated through inhibition of dynorphin degradation. Tan-No K; Takahashi H; Nakagawasai O; Niijima F; Sato T; Satoh S; Sakurada S; Marinova Z; Yakovleva T; Bakalkin G; Terenius L; Tadano T Pain; 2005 Feb; 113(3):301-309. PubMed ID: 15661437 [TBL] [Abstract][Full Text] [Related]
11. Opioid receptor selectivity of dynorphin gene products. James IF; Fischli W; Goldstein A J Pharmacol Exp Ther; 1984 Jan; 228(1):88-93. PubMed ID: 6141278 [TBL] [Abstract][Full Text] [Related]
13. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist. Patkar KA; Yan X; Murray TF; Aldrich JV J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987 [TBL] [Abstract][Full Text] [Related]
14. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function. Long JB; Petras JM; Mobley WC; Holaday JW J Pharmacol Exp Ther; 1988 Sep; 246(3):1167-74. PubMed ID: 2901487 [TBL] [Abstract][Full Text] [Related]
15. Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation. Paterlini G; Portoghese PS; Ferguson DM J Med Chem; 1997 Sep; 40(20):3254-62. PubMed ID: 9379445 [TBL] [Abstract][Full Text] [Related]
16. A novel soluble protein factor with non-opioid dynorphin A-binding activity. Marinova Z; Yakovleva T; Melzig MF; Hallberg M; Nylander I; Ray K; Rodgers DW; Hauser KF; Ekström TJ; Bakalkin G Biochem Biophys Res Commun; 2004 Aug; 321(1):202-9. PubMed ID: 15358236 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3. Vig BS; Murray TF; Aldrich JV J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314 [TBL] [Abstract][Full Text] [Related]
18. Kappa opioid control of seizures produced by a virus in an animal model. Solbrig MV; Adrian R; Baratta J; Lauterborn JC; Koob GF Brain; 2006 Mar; 129(Pt 3):642-54. PubMed ID: 16399805 [TBL] [Abstract][Full Text] [Related]
19. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Kuzmin A; Madjid N; Terenius L; Ogren SO; Bakalkin G Neuropsychopharmacology; 2006 Sep; 31(9):1928-37. PubMed ID: 16292317 [TBL] [Abstract][Full Text] [Related]
20. Dynorphin A (1-13): in vivo opioid antagonist actions and non-opioid anticonvulsant effects in the rat flurothyl test. Tortella FC; Holaday JW NIDA Res Monogr; 1986; 75():539-42. PubMed ID: 2893282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]